We have previously shown that the human papillomavirus E7 proteins bind to the cellular TATA box binding protein (TBP). In this paper we show that the HPV-18 E6 and the HPV-16 E2 proteins will also bind TBP in vitro. This feature of virus proteins is conserved across many viral types and we were interested in determining whether these HPV proteins interacted with the same conserved region of the TBP molecule. A series of deletions was introduced into the TBP protein and its binding to these HPV proteins was measured. The previously well-characterized interaction between p53 and TBP was used for comparison. All four proteins were found to interact with the carboxy-terminal domain 0001-4911 # 1997 SGM 
Introduction
Papillomaviruses cause epithelial proliferations in humans and other animals ; in humans the type of lesion caused has been shown to correlate with a specific human papillomavirus (HPV) type. More than 70 types of HPV have been isolated (de Villiers, 1989 ) and a subset of these infect the mucosa of the anogenital tract. This subset can be subdivided into two groups : ' the low risk ' HPVs (including types 6 and 11), which are very rarely found in malignant tumours but induce benign genital warts and low grade cervical intraepithelial lesions (Du$ rst et al., 1983 ; Gissmann et al., 1983) , and the ' high risk ' HPVs (including types 16 and 18), which have been found in invasive carcinomas of the cervix (zur Hausen & Schneider, 1987) .
In most cases of cervical cancer the HPV DNA is integrated into the cellular genome and this usually occurs within the viral E1 or E2 open reading frames (Schwarz et al., 1985 ; Yee et al., 1985) . However, the early viral gene region, in particular E6 Author for correspondence : Lawrence Banks.
Fax j39 40 226 555. e-mail Banks!icgeb.trieste.it of the TBP protein, although the precise residues involved and the relative strengths of association differed between the different HPV proteins. Mutational analysis of HPV-16 E7 protein identified a stretch of four amino acids responsible for the binding to TBP. This mutant E7 protein possessed wild-type levels of transcriptional activity on the adenovirus E2 promoter but exhibited reduced transforming activity in cooperation with EJ-ras. These results demonstrate that the mechanisms of interaction between diverse viral proteins and TBP are similar and that, in the case of E7, this interaction may contribute to its transforming activity. and E7, is selectively retained and expressed both in cervical cancer biopsies and in derived cell lines (Smotkin & Wettstein, 1986 ; Banks et al., 1987 ; Androphy et al., 1987) . Several reports have shown that the HPV-16 E7 gene encodes the major transforming activity of the virus. The E7 protein can transform primary rodent cells in cooperation with an activated oncogene (Matlashewski et al., 1987 ; Phelps et al., 1988 ; Storey et al., 1988) and, in cooperation with E6, will immortalize primary human keratinocytes (Hawley-Nelson et al., 1989 ; Mu$ nger et al., 1989) .
A large number of studies have shown that E7 binds to many of the same cellular targets as adenovirus E1a and simian virus 40 large T antigen. Thus, E7 has been shown to bind pRb, p107, cyclin A and the AP-1 family of transcription factors (Dyson et al., 1989 ; Davies et al., 1993 ; Tommasino et al., 1993 ; Antinore et al., 1996) . Recent studies have also shown that E7 can complex with the TATA box binding protein (TBP) in a manner similar to that reported for E1a . In this case, it was found that the interaction between E7 and TBP was significantly enhanced following casein kinase II (CKII) phosphorylation of the E7 protein.
Many viral and cellular proteins have been shown to bind TBP and of particular relevance for papillomaviruses are the studies which have shown binding between TBP and the viral E2 protein (Steger et al., 1995 ; Rank & Lambert, 1995) and between TBP and the cellular tumour suppressor p53 (Seto et al., 1992 ; Liu et al., 1993) . We were therefore interested in analysing further the mechanism of interaction between E7 and TBP, comparing this with other proteins also known to interact with TBP and determining the relevance of the E7-TBP interaction to the transforming activity of E7. We show that HPV-16 E7, HPV-16 E2, HPV-18 E6 and the cellular tumour suppressor p53 all bind to the same conserved carboxyterminal region of the TBP molecule. In addition, mutational analysis of the HPV-16 E7 protein has identified a region within the carboxy terminus of the E7 protein which is responsible for the basic interaction with TBP in the absence of CKII phosphorylation. This mutant E7 protein was found to exhibit wild-type levels of transcriptional activity on the adenovirus E2 promoter and, hence, equal levels of affinity for pRb and equal levels of expression in vivo. Interestingly, this mutant was found to be significantly reduced in its ability to cooperate with EJ-ras in the transformation of primary rodent cells, when compared with the wild-type E7 protein. These results define a common domain of the TBP molecule which is bound by several HPV proteins. Most significantly, HPV-16 E7 binding to TBP would appear to contribute to its ability to transform primary cells in cooperation with EJ-ras.
Methods
Plasmids. The SP64 plasmids containing E7, E2, E6 and p53 used for in vitro transcription and translation have been described previously Bouvard et al., 1994 ; Pim et al., 1994) . GST fusion proteins were obtained by cloning TBP and the deletion mutants of TBP into the BamHI\EcoRI sites of pGEX-2T. For in vivo expression studies pJ4Ω was used and this has been described previously (Matlashewski et al., 1987) , as have the adenovirus E2 CAT reporter plasmid (Storey et al., 1990) and the EJ-ras expressing plasmid (Matlashewski et al., 1987) .
GST fusion protein expression and in vitro binding assays.
Induction of the GST fusion proteins and their subsequent purification for use in protein binding assays was done as described previously . Proteins were in vitro translated using the TT system (Promega) and the binding assays were also performed as described previously , with modifications in the salt concentrations as described in the text.
In vitro mutagenesis. Mutagenesis was done using PCR directed mutagenesis followed by cloning into the appropriate expression plasmid. All mutants were verified by DNA sequencing.
Transfections and CAT assays. All transfections were carried out using the standard calcium phosphate precipitation procedure (Matlashewski et al., 1987) . Transformation assays were done by cotransfecting primary baby rat kidney (BRK) cells from 9-day-old Wistar rats with 5 µg pJ4Ω.16E7 or the appropriate mutant together with 5 µg EJ-ras expressing plasmid and 3 µg pSV2neo. Cells were placed in selection medium containing 200 µg\ml G418 and the colonies allowed to develop for 2 weeks. After this time the dishes were fixed and stained and colonies counted.
Adenovirus E2 promoter CAT assays were done in NIH3T3 cells as described previously (Pim et al., 1994) .
Western blot analysis.
Cell extracts were made as described previously (Thomas et al., 1996) and, following transfer to nitrocellulose membrane, E7 protein was detected using an anti-E7 polyclonal antibody and developed using the ECL system (Amersham), according to the manufacturer's instructions.
Results

Diverse HPV proteins bind to the same conserved carboxy-terminal region of TBP
We have previously shown that HPV-16 E7 will bind to the TBP and that this interaction is stimulated by CKII phosphorylation of the E7 protein . However, E7 will still bind TBP to a significant degree in the absence of CKII phosphorylation, suggesting there is a region on the E7 protein responsible for the initial interaction with TBP which is separate from the CKII recognition site. In addition, although we know that E7 binds to the carboxy-terminal half of TBP the precise region of the TBP molecule has not been identified. We were therefore interested first in identifying the region on TBP which was bound by E7 and then comparing this with other proteins known to associate with TBP. To identify the region of TBP bound by HPV-16 E7, we constructed a series of TBP deletion mutants and expressed them as GST fusion proteins. The full-length TBP used in this study was obtained by reverse transcription of HeLa mRNA followed by PCR amplification. The DNA fragments corresponding to clone 1 (∆ amino acids 1-201), clone 2 (∆ amino acids 100-339), clone 3 (∆ amino acids 272-339) and clone 4 (∆ amino acids 298-339) were obtained by PCR amplification using full-length TBP as the template, followed by cloning into the BamHI\EcoRI sites of pGEX-2T. These mutants are shown schematically in Fig. 1 (a) . Fusion proteins were expressed and purified as described previously and the protein profiles of the purified mutant fusion proteins are shown in Fig. 1 (b ).
Previous reports have described the binding of p53, HPV-16 E7 and BPV-1 E2 to TBP (Seto et al., 1992 ; Liu et al., 1993 ; Rank & Lambert, 1995 ; Steger et al., 1995 ; Massimi et al., 1996) . In addition, during the course of our studies, we noted that HPV-18 E6 could bind TBP in vitro (P. Massimi, personal observations). We were therefore interested in determining whether this diverse group of proteins bound to the same region of TBP. To do this, the mutant TBP fusion proteins were expressed and purified from bacteria and then incubated with in vitro translated radiolabelled p53, HPV-16 E7, HPV-16 E2 and HPV-18 E6. Although similar studies have previously been performed for p53 (Martin et al., 1993) , we were interested in comparing directly the ability of p53 to bind different regions of TBP with that of the viral proteins. Binding reactions were performed in PBS at 4 mC for 1 h and, following extensive washing, bound proteins were analysed by PAGE and autoradiography . The results of the GST-TBP fusion proteins (FL being fulllength TBP) were induced and purified to the levels shown in Fig. 1 (b) and then incubated with in vitro translated radiolabelled E2, E6, E7 and p53 as indicated. After extensive washing the bound proteins were determined by PAGE and autoradiography. Fig. 3 . Comparison of the relative strengths of p53, E2, E6 and E7 binding to TBP. Full-length GST-TBP fusion protein was prepared as described above and incubated with in vitro translated radiolabelled p53, E2, E6 and E7 as indicated. Bound proteins were then washed in increasing concentrations of NaCl, as shown, and the remaining protein determined by PAGE and autoradiography.
in vitro binding assays are shown in Fig. 2 and reveal a number of interesting points. First, none of the proteins tested show any significant binding to the M2 fusion protein. This mutant lacks the carboxy-terminal region of TBP and demonstrates that E2, E6, E7 and p53 all bind to the conserved carboxyterminal region of the TBP molecule. Second, the pattern of binding of p53 is broadly similar to that previously reported (Martin et al., 1993) . Although binding is much weaker on the M1, M3 and M4 fusion proteins compared with the full-length TBP, it is nonetheless detectable and indicates that residues 201-272 of the TBP molecule are required for p53 binding, although residues 100-201 would also seem to be important. Interestingly, a very similar pattern of binding is obtained with the E6 protein and this suggests that E6 and p53 may bind TBP in a very similar manner. In contrast, E7 binds the M1, M3 and M4 fusion proteins almost as strongly as the full-length TBP fusion protein. This result indicates that residues 100-201 on TBP have no role in E7 binding and, further, that the region of TBP responsible for E7 binding lies entirely within residues 201-272. A similar situation seems to hold true for HPV-16 E2 and indicates strong similarity between E2 and E7 in their binding to TBP. These results demonstrate that this group of proteins all bind within the same carboxy-terminal region of the TBP molecule but that there are clear differences in the precise residues involved. Having shown that differences exist in the precise nature of the interactions between the viral proteins and TBP, we were then interested in investigating further the relative strengths of these interactions. Obviously, within the context of a viral infection, differences could have important implications in terms of competition for the available TBP. To study this, the binding assays were repeated using a purified full-length GST-TBP fusion protein, together with in vitro translated E2, E6, E7 and p53. Following incubation at 4 mC for 1 h, the bound proteins were exposed to salt concentrations ranging from 0n17 to 4 M NaCl. After washing, the retained proteins were monitored by PAGE and autoradiography. The results obtained are shown in Fig. 3 and show interesting differences in the relative susceptibility of the different viral protein-TBP interactions to salt disruption. The most easily disrupted seems to be that between E2 and TBP since 1 M NaCl almost abolishes this interaction. Considering that E2 is a major regulator of viral gene expression and its diverse effects have been postulated to occur through interaction with the basic transcriptional machinery, including TBP (Ushikai et al., 1994 ; Rank & Lambert, 1995 ; Steger et al., 1995) , this is quite a surprising result. On the other hand, HPV-18 E6 and p53 show very similar strengths of interaction with TBP, with weak binding seen following 1 M NaCl treatment, but complete disruption by the 2 M NaCl wash. The strongest interaction is seen between E7 and TBP. Strong binding between the two proteins is still seen after the 2 M NaCl treatment and only after washing in 4 M NaCl is the interaction completely disrupted. These results thus demonstrate a hierarchy between the HPV proteins for binding TBP, with E7 being the strongest, followed by E6 and finally the weakest interaction being observed with E2.
HPV-16 E7 binding to TBP contributes to its transforming activity
Having characterized the region of TBP bound by E7 we were then interested in determining whether E7 binding to TBP contributed to its transforming activity. Indeed, previous studies using an E7 mutated in its CKII recognition site, which has reduced binding to TBP, would predict that the TBP association may play a role, since the non-phosphorylatable mutant exhibits reduced levels of transforming activity (Barbosa et al., 1990) . To verify this, however, it was necessary to identify the region of E7 responsible for the initial binding to TBP. We therefore constructed a series of carboxy-terminal deletion mutants of E7 and these are shown in Fig. 4 . Our reasoning behind the construction of this set of mutants was that the amino-terminal mutants of E7 available to us retained the ability to bind to TBP (P. Massimi, personal observations). We then proceeded to investigate the ability of this new series of mutants to bind TBP. The mutant E7 proteins were in vitro translated as above, and incubated with equal quantities of GST-TBP. Following extensive washing, the bound E7 protein was detected by PAGE and autoradiography. The results obtained are shown in Fig. 5 . It is clear that mutants ∆65-67 and ∆75-77 bind TBP with an efficiency similar to that of the wild-type E7 protein. In marked contrast, mutant ∆79-83 retains only minimal binding to TBP. This result indicates that the region of E7 spanning amino acids 79-83 is essential for binding to TBP.
We were next interested in investigating the ability of these mutant proteins to cooperate with an activated ras oncogene in the transformation of primary BRK cells. BRK cells were prepared from 9-day-old Wistar rats and transfected with the different mutant E7 genes cloned in plasmid pJ4Ω, together with EJ-ras and a selectable marker. After 2 weeks the dishes were fixed and stained and the colonies counted. The results from a series of transformation assays are shown in Table 1 . It is clear that mutant ∆65-67 has essentially wild-type levels of transforming activity and mutant ∆75-77 is only slightly reduced when compared with the wild-type E7. In contrast, mutant ∆79-83 has a significantly reduced (P 0n001 by χ#) ability to cooperate with EJ-ras in the transformation of primary BRK cells. These results indicate that the region of the E7 protein spanning residues 79-83 has a role in its transforming activity. In order to verify that the ∆79-83 mutant produced stable protein a Western blot analysis of E7 expression was done on clones derived from the transformation assay. The results obtained are shown in Fig. 6 and demonstrate that the ∆79-83 mutant is expressed at a level similar to that of the wild-type E7. Another possible explanation for the reduced transforming activity of the ∆79-83 mutant could be its reduced binding to pRb and consequent reduced induction of E2F transcriptional Fig. 7 . Comparison of the abilities of the different E7 mutants to activate transcription from the adenovirus E2 promoter. NIH3T3 cells were transfected with 3 µg of the AdE2 CAT plasmid together with 5 µg of pJ4Ω control, wild-type E7 or the indicated mutant. After 48 h cells were harvested and CAT activity was measured. The results show the mean percentage CAT conversion from three independent experiments. Standard deviations are shown. activity. To investigate this possibility we performed a series of transcriptional activation assays on the adenovirus E2 promoter with the different E7 mutants. Cells were transfected with the adenovirus E2 CAT reporter plasmid together with wild-type and mutant E7 expressed in pJ4Ω. The results obtained are shown in Fig. 7 . All three mutants possess an ability to activate the adenovirus E2 promoter similar to the wild-type E7 protein. These results demonstrate that the reduced level of transforming activity observed with the ∆79-83 mutant is not due to reduced E2F activation, but is most likely to be due to its inability to bind TBP.
Discussion
In this study we have shown that the HPV proteins E2, E6 and E7, together with the cellular tumour suppressor protein p53, all bind to the same conserved carboxy-terminal region of TBP. However, the precise residues on the TBP molecule responsible for binding this diverse group of proteins are clearly different. In the case of HPV-16 E7 we have also identified the region of the E7 protein responsible for binding TBP and this appears to contribute to the ability of E7 to transform primary BRK cells in cooperation with EJ-ras.
Although p53, HPV-16 E2, HPV-16 E7 and HPV-18 E6 bind to a similar region of the TBP molecule the relative stability of the interactions, as determined by resistance to disruption in high salt concentrations, is different. In addition, this stability of binding to TBP does not necessarily reflect the known activities of these proteins in vivo. The HPV-16 E7, HPV-16 E2, HPV-18 E6 and p53 proteins all possess an intrinsic transcriptional activity (Phelps et al., 1988 ; Phelps & Howley, 1987 ; Sedman et al., 1991 ; Kern et al., 1991) and for p53 and BPV-1 E2 this has been shown to be related, in part, to their ability to bind TBP (Seto et al., 1992 ; Liu et al., 1993 ; Steger et al., 1995) . This is not the case for E6 and it remains to be determined whether TBP binding by this protein reflects its in vivo activities. In the case of E7, however, we have been able to demonstrate that binding TBP may play a role in its transforming activity. Mutational analysis of HPV-16 E7 identified a region of the carboxy-terminal half of the protein, spanning amino acid residues 79-83 which, when deleted, resulted in a loss of binding to TBP. Two other mutants within the same region of E7, spanning amino acid residues 65-67 and 75-77, retained wild-type levels of binding to TBP, indicating that disruption of binding was not due to a general perturbation of the structure of the carboxy-terminal half of E7 as a result of the amino acid deletions. Analysis of these mutants of E7 for their ability to transform primary BRK cells demonstrated that the ∆79-83 mutant, which was defective in TBP binding, was also reduced in its ability to transform cells in cooperation with EJ-ras. Mutants ∆65-67 and ∆75-77, which retained wild-type levels of TBP binding, also retained wild-type levels of transforming activity. The importance of TBP binding for the transforming activity of E7 is also supported by previous studies. We have shown that CKII phosphorylation of E7 greatly enhances its ability to bind TBP and, as yet, no other function has been proposed for the CKII phosphorylation of E7. It has also been shown that mutation of the CKII site on E7 results in reduced transforming activity (Barbosa et al., 1990) , and this is consistent with reduced binding to TBP.
We have shown that the reduction in the transforming activity of mutant ∆79-83 was not due to a reduction in induction of E2F, since all three mutants retained wild-type levels of transcriptional activity on the adenovirus E2 promoter. These results also confirm that the ∆79-83 mutant is stable in vivo, a point which we have also verified by Western blot analysis of the transformed BRK cell lines. Although mutant ∆79-83 is reduced in its ability to transform cells, colonies are nonetheless obtained. This is not too surprising since it has been shown that only regions around the pRb binding pocket and within the extreme amino terminus of E7 are absolutely essential for the transforming activity of E7 (Edmonds & Vousden, 1989 ; Banks et al., 1990) . Therefore, binding TBP is only contributory to the transforming activity of E7.
These studies raise the question of how the E7 TBP interaction might be involved in the ability of E7 to transform cells. The obvious conclusion would be that E7, through its interaction with TBP, may activate expression of some as yet unknown cellular genes which aid the transformation process. However, recent studies indicate that E7-TBP binding correlates with the ability of E7 to inhibit p53 transcriptional activity (Massimi & Banks, 1997) . Based on the data presented here this suggests an alternative mechanism for this activity of E7, since E7 binds TBP with an apparently higher affinity than that between TBP and p53. Therefore, E7 may be able to perturb the p53-TBP-transcription factor complex, resulting in an inhibition of p53 transcriptional activity.
In conclusion, we have mapped the binding sites of a diverse group of HPV proteins on the TBP molecule and shown that the HPV-16 E7-TBP interaction contributes to the ability of E7 to transform primary rodent epithelial cells. Studies currently in progress are aimed at determining whether the E7-TBP interaction is regulated through the cell cycle.
